|
|
 |
|
Latest News
|
| |
| |
|
|
|
| |
 Structure-flex opens supply chain route with China
|
| |
Melton Constable, Norfolk: in today’s extremely difficult economic climate, when competitors are hungry for your business, it is of paramount importance to ensure that your existing and potential customers can be supplied with first-class products, on time, and at competitive prices. Happily, this is a business ethic that Structure-flex Limited of Melton Constable in North Norfolk has embraced for many years, and to satisfy demand for its packaging solutions, the company has recently sourced an FIBC supplier in China.
Structure-flex has a reputation for the development and manufacture of FIBC Bulk Bags, and is a recognised leading supplier to many market segments, including major ‘Blue Chip’ companies. The FIBCs are used for the transport and storage of a full range of materials from the food and drinks industries, pharmaceutical and chemical industries and waste by-products.
 Terry Scannell, Supply Chain Manager at Structure-flex comments: “The FIBC market is a fast moving industry, where the demands of the consumer dictate short lead times and J.I.T. deliveries of the highest quality products at ultra-competitive prices. In the past, Structure-flex has manufactured products from its own facility; however, as a result of the rapid increase in global trading opportunities and the growth of customers’ own markets, the industry has seen the development of new overseas supply routes which can offer products of the highest quality whilst maintaining excellent value for money.”
Structure-flex has fully embraced these changes. It has devoted a great deal of time and resources to ensure that its position as a market leader is maintained, and that, through working with supply partners, it can continue to offer the highest standard of service to its customers. To this end, the Purchasing Department has undertaken a full review of all key potential FIBC suppliers. |
|
“It became clear that there is a strong core of experienced manufacturers based in the highly industrialised area around Shanghai in China which would be worth a visit,” Terry goes on to explain. “The fact-finding mission proved to be a worthwhile exercise, underlining the vast differences between suppliers and the importance of applying our own quality audit / vendor rating system when choosing which company to work with.
“However, as a result of this process we found three potential supply partners that were able to meet our stringent criteria, which includes the ability to design and manufacture to the highest quality specifications, to be able to work to tight deadlines with regard to shipping requirements, and with excellent technical, commercial and communications strengths within their work force.”
Structure-flex has now received its first production runs from its preferred Chinese supplier, which have achieved all its objectives.
Matt Doughty, Head of Sales and Marketing at Structure-flex, is very satisfied with this most recent supply partnership, saying: “The Chinese supply option opens up our potential marketing place, providing an AIB food grade approved source that enables Structure-flex to compete in the high volume, low cost segment. FIBCs from China will complement products from our existing European suppliers. We are now able to offer a cost-effective, high quality product with the reassurance of recognised quality standards, and still provide the same degree of technical and logistical support. The supplier review / vendor rating programme served us well in China, and will continue to be used by the purchasing team to monitor the performance and quality of our FIBC partners. Our customers can have confidence in our product range wherever they are sourced.”
|
| |
| Prefilled WFI Syringe Provides a High-Quality Solution for Drug Reconstitution |
| |
Ravensburg, May 8, 2009 - West (NYSE: WST), the world’s premier manufacturer of components and systems for injectable drug delivery, and Vetter, a worldwide leading independent specialist in the contract manufacturing of prefilled application systems, have introduced a ready-to-use, WFI prefilled syringe for reconstituting lyophilized drug products.
“The Vetter/West WFI syringe combines the best of pharmaceutical components in a drug administration system that we believe customers will embrace,” said Mike Schaefers, Vice President, Marketing, Europe, West. “This system can be applied to our customers’ high-value pharmaceutical and biopharmaceutical drug products.”
“This system unites two of the world’s leaders in drug administration systems and pharmaceutical processing,” said Oskar Gold, Vice President, Key Account Management, Vetter. “We are pleased that we can offer customers a world-class prefilled syringe system.”
The syringe features a plunger with West’s FluroTec® barrier film and Vetter’s V-OVS® tamper-evident closure, which includes a West tip cap. The film, developed by West’s partner, Daikyo Seiko, Ltd., provides an effective barrier against organic and inorganic extractables, which helps maintain the purity of the diluent.
The V-OVS® closure system is designed to give a prefilled syringe system effective protection features. It consists of a tip cap, a Vetter Luer Lock and a tamper-evident seal. The components are pre-assembled as a single part, which is mounted on the syringe barrel with a Luer-cone and Luer-groove. The integrity of the syringe system is maintained if the seal has not been broken.
The syringes are available with fill volumes between 0.5mL and 3.0mL. The glass syringe barrels are treated with baked silicone for lubricity and are 100 percent visually inspected to provide highest quality levels.
Customers will have packaging options, including individual blister packaging.
Vetter fills and terminally sterilizes the syringe at its facility in Langenargen, Germany. The syringes are supplied with regulatory documentation to meet requirements of markets in Europe, Japan, North America and numerous other countries. |
|
 For more information contact
Vetter Pharma International GmbH
Oskar Gold
Eywiesenstrasse 5
88212 Ravensburg
Germany
phone: +49-(0)751-3700 - 0
fax: +49-(0)751-3700 - 40 00
e-mail: info@vetter-pharma.com
www.vetter-pharma.com
About West
West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.
About Vetter
Vetter is an independent international specialist in the production of aseptically pre-filled injection systems, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. With about 1,900 employees worldwide, Vetter holds about 140 patents and has longstanding experience in handling client products and processes approved by the FDA, EMEA and other authorities.
FluroTec® is a registered trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
FluroTec technology is licensed from Daikyo Seiko, Ltd.
Vetter and V-OVS® are registered trademarks of Vetter Pharma-Fertigung GmbH& Co.KG in Germany, the United States and other jurisdictions.
MixJect® is a registered trademark of Medimop Medical Projects Inc.
|
| |
| Pfeiffer invests EUR 12 million in new logistics and technology centres |
| |
Pfeiffer invests EUR 12 million in new logistics and technology centres - Extensive pharmaceutical division building programme in Germany focuses on current and future customer needs
(Radolfzell, Germany, 22 April 2009) - Pfeiffer, a leading manufacturer of pharmaceutical pumps, is investing EUR 12 million in a new building project at its main manufacturing plant in Eigeltingen, Germany. A logistics centre and a new technical centre, covering a combined floor area of over 6,500 m², will both go into full operation in 2009. The logistics centre incorporates high bay racking, dedicated delivery and dispatch areas, plus a state-of-the-art packaging facility. In the technical centre, tools will be built, tested, maintained and repaired by the on-site experts. The new premises enable optimal process efficiency, allowing Pfeiffer to meet customer needs in an increasingly competitive, highly regulated market environment.
Multiple benefits
The increased capacity and operational efficiency of the new logistics centre, in use since January 2009, translates directly into measurable benefits for staff and customers. Its spacious architecture, integrating maximum daylight, provides a modern, ecologically responsible working environment. Excellent hygienic conditions, including plastic palettes, the total elimination of cardboard, and air screens preventing contamination from the integrated loading bays, bring clear advantages to customers. The new centre also includes an incoming laboratory, where all materials delivered are checked in accordance with the stringent Pfeiffer quality standards. This completes the quality circle, ensuring optimal efficiency from start to finish of the logistics chain. Drivers collecting goods from the plant also have automatic access to self-contained showering and rest facilities adjacent to the office area for the dispatch administration services. The technical centre will go into operation in August 2009 with its industrialisation and tooling services covering an area across 3,375 m² on two floors.
Building the future
Thomas Klofac, President of the Pfeiffer Pharma Division, explains that the current investment programme is geared to meeting growing demand, particularly for the new Pfeiffer ophthalmic products, electronic dispensing technology and systems for preservative-free substances. Extending the facilities in Eigeltingen also reconfirms the company’s proven commitment to German engineering. He concludes, “Pfeiffer is committed to maintaining long-term relationships with employees, suppliers and customers. Our new facilities are proof of this commitment and our key to being able to react to market needs today and tomorrow.” |
|
Pfeiffer at a glance
The company Ing. Erich Pfeiffer GmbH was founded in 1947. Today the company is one of the world’s leading pharmaceutical pump manufacturers and has 600 employees. The company headquarters are in Radolfzell in Southern Germany with the main production facilities in nearby Eigeltingen. Pfeiffer also is represented across all five continents via an extensive network of sales offices. The Pfeiffer pharmaceutical product portfolio encompasses a wide range of dispensing systems for drug administration via the nasal, oral, dermal and ophthalmic routes.
www.pfeiffer-group.com
Facts and Figures – New Facilities
| Total financial investment |
EUR 12 million |
| Project start date – logistics centre |
February 2008 |
| Project completion date – logistics centre |
January 2009 |
| Project start date – technical centre |
August 2008 |
| Project completion date – technical centre |
End of July 2009 |
| Total usable surface area |
6510 m² |
| Surface area – logistics centre |
3135 m² |
| Surface area – technical centre |
3375 m² |
 |
| |
|
|
|
| |
| Vetter launches Project Management Quality Assurance Program |
| |
Vetter launches Project Management Quality Assurance Program
Employees to receive IPMA certification
Ravensburg, April 7, 2009 – With a new state-of-the-art project management program, Vetter will help pharmaceutical and biotech companies to better control the quality and costs of their pre-filled injectable product manufacturing processes. As a specialist in the aseptic filling of syringes, cartridges and vials, Vetter has launched an extensive quality assurance program for its project managers, which ultimately should lead to their certification by the International Project Management Association (IPMA).
Vetter expects the program to further boost its efficiency. In today’s competitive international markets, pharmaceutical and biotechnology companies receive a boost from smooth processes and short throughput times, which help get products to market more quickly.
“Before commercial manufacturing ever begins, we spend years working together with the customer on packaging and production processes,” said Jochen Alberstetter, Vice President of Project Management for Vetter. First, the basic tools of project management were introduced in the entire company. “By undergoing an IPMA audit, we can now help our clients benefit from the highest-quality project management available.”
The IPMA has set up a rigorous process to test project managers and ensure they are prepared for the tasks that lie ahead. Each participant in the certification program must have at least three years of experience in project management, plus two years of practical work leading a project.
The candidate is assessed on a wide variety of criteria, including the ability to plan, control, communicate and solve problems. Certification then is awarded to those who demonstrate deep organizational knowledge, as well as leadership qualities.
IPMA is a world leading project management organization that currently represents 45 national project management associations and over 55,000 members on the international level. The IPMA has a strong presence in Europe as well as North and South America, Asia and Africa. Because of the proximity to Austria, the IPMA certification was carried out by Project Management Austria (PMA). |
|
For more information contact
Vetter Pharma International GmbH
Oskar Gold
Eywiesenstrasse 5
88212 Ravensburg
Germany
phone: +49-(0)751-3700 - 0
fax: +49-(0)751-3700 - 40 00
e-mail: info@vetter-pharma.com
www.vetter-pharma.com
About Vetter:
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities.
Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions’ patented application systems enable clients to compete more effectively throughout the world. |
| |
| |
| As GPCR Space Becomes More Crowded, Drug Makers Show Affinity for Non-traditional GPCR Binding Sites |
| |
As GPCR Space Becomes More Crowded, Drug Makers Show Affinity for Non-traditional GPCR Binding SitesNew service from Millipore reveals selectivity of novel allosteric drugs
Billerica, Mass. – April 5, 2009 – Millipore Corporation
(NYSE: MIL) today announced the release of their AllostericProfiler™ service for use by researchers developing new drugs using G-protein coupled receptors (GPCRs), an important class of proteins for the treatment of multiple diseases and also drug side-effects.
Although 40% of all marketed drugs are targeted to G-protein coupled receptors (GPCRs), the similarity of GPCR binding sites coupled with saturated intellectual property around this chemical space have hampered GPCR drug discovery efforts. Increasingly, drug makers are instead focusing on novel allosteric GPCR sites to open up new chemical spaces. (Allosteric GPCR binding sites modulate native ligand binding sites and are potentially more specific.)
Facilitating the research of allosteric sites, Millipore’s AllostericProfiler™ service is the first to provide drug developers with cell-based assays to evaluate the functional selectivity of drugs against GPCRs.
“Allosteric modulators of GPCRs provide exciting new opportunities to discover and develop selective activators and inhibitors of GPCRs that have proven intractable when targeting orthosteric sites,” said Dr. Jeffrey Conn, Director of the Vanderbilt Program in Drug Discovery within the Department of Pharmacology at the Vanderbilt University Medical Center. “Our new understanding of allosteric modulation of GPCRs forces a shift in our thinking about approaches to panel screening for selectivity of novel agents and suggests that it is critical to employ functional panel screens of GPCR selectivity rather than relying exclusively on radioligand binding,” Conn added.
|
|
Millipore’s AllostericProfiler service allows researchers to screen the selectivity of their allosteric compounds for over 150 different GPCRs. Millipore can also provide custom services (AllostericScreener™ service) to help researchers identify new positive allosteric modulators for a GPCR target of interest.
By using a unique two-step addition protocol, the AllostericProfiler service detects both orthosteric compounds (which bind the native site) as well as allosteric modulators. First, the test compound is added to cells stably expressing a GPCR to determine whether the compound has agonist activity. Second, a dose response of a reference agonist, typically the native ligand, is added in the presence or absence of the test compound to compare how the test compound changes the reference agonist’s potency and efficacy. These changes can reveal activities ranging from positive to negative allosteric modulation.
“The search for druggable allosteric sites on GPCRs has begun in earnest,” observed Blaine Armbruster, Millipore Product Manager for GPCR Drug Discovery. “The therapeutics Cinacalcet (for hyperparathyroidism) and Maraviroc (for HIV) are both allosteric GPCR modulators and more GPCR-modulating drugs are in development.”
The AllostericProfiler service is the latest addition to Millipore’s GPCRProfiler® service offering, which was launched by Millipore in 2006 as the first outsourced cell-based functional assay service for GPCR profiling using Millipore’s robust ChemiScreen™ GPCR cell lines.
About Millipore:
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
Millipore Media Contact:
Greg Hoff, Media Relations, Bioscience Division
978-762-5170 or
greg_hoff@millipore.com
Millipore and GPCRProfiler are registered trademarks and the “M” logo. AllostericProfiler, AllostericScreener, ChemiScreen, and ADVANCING LIFE SCIENCE TOGETHER are trademarks of Millipore Corporation. |
| |
| Millipore Introduces New Tools for Vascular Biology Research |
| |
Millipore Introduces New Tools for Vascular Biology Research
New line of cells and optimized media improve growth and morphology of in vitro models
Billerica, Mass. – March 25, 2009 - Millipore Corporation (NYSE: MIL) today announced the release of EndoGRO™ products for vascular research, including human umbilical vein endothelial cells (HUVEC) and advanced media formulations for endothelial cell culture. Endothelial cells play a key role in a range of biological processes. In vitro cell models are commonly used for physiological and pharmacological investigations of angiogenesis, clotting, and inflammation, as well as arteriosclerosis and vascular disorders. EndoGRO advanced media products include four uniquely optimized formulations for large vessel and microvascular endothelial cells, as well as low-passage HUVEC.
EndoGRO media formulations have lower serum concentrations than standard endothelial cell culture media, yet have been shown to support endothelial cell growth rates that exceed other commercially available serum-containing media, while maintaining excellent cell morphology. In addition, the media have no phenol red or antimicrobials, which can cause cell stress and mask natural biological processes.
EndoGRO human umbilical vein endothelial cells are cultured for only one passage before cryopreservation to ensure the highest viability and culture life. Growth of these cells is enhanced by the use of EndoGRO media. EndoGRO cells and media are part of Millipore’s expanding selection of specialty cell culture tools. More information is available at www.millipore.com/cellbiology. |
|
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, please contact Millipore Tech Service at
1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHERTM
Research. Development. Production.
Millipore Media Contact
Greg Hoff
Media Relations Bioscience Division978-762-5170
greg_hoff@millipore.com |
| |
| Vetter Pharma Fertigung GmbH & Co. KG Launches New Subsidiary |
| |
Vetter Pharma Fertigung GmbH & Co. KG Launches New Subsidiary
Vetter Pharma International GmbH (VPI) will Focus on Global Sales, Service
Ravensburg, Germany – Vetter Pharma-Fertigung GmbH & Co. KG (VPF) today announced the formation of a new subsidiary, Vetter Pharma International GmbH (VPI). With a scheduled launch date of April 1, 2009, VPI will be responsible for all Vetter sales, marketing and customer service activities on a worldwide level.
Peter Soelkner has been named Managing Director, and Oskar Gold will serve as Vice President of the new entity. Headquarters will be in Ravensburg, Germany, and Vetter Pharma International USA Inc. will be located in Yardley, PA.
“The formation of VPI allows us to better position ourselves as a worldwide leader in pre-filled aseptic injection solutions,” Soelkner said. “By creating an entity that focuses exclusively on sales, marketing and customer service on a global level, Vetter will move significantly closer to the international market and can build even stronger relationships with our clients and prospects throughout the world.”
VPF, which previously has managed all of Vetter’s sales, services and manufacturing activities under a single corporate umbrella, will now focus exclusively on the company’s manufacturing and pharmaceutical operations. VPF will continue to be a strong partner for pharmaceutical and biotech companies, providing high quality pharmaceutical services that support the supply chain of aseptically pre-filled injectable products, from clinical development to market launch to ongoing delivery worldwide, Soelkner said.
“By realigning our resources to empower each entity’s core competencies, both VPI and VPF alike can be major catalysts in Vetter’s continued growth and expansion in the years to come—no matter how much the industry may change,” he added.
|
|
For more information contact:
Vetter Pharma-Fertigung GmbH &
Co. KG
Oskar Gold
Schuetzenstrasse 87
88212 Ravensburg
Germany
Phone: +49-(0)751-3700 - 0
Fax: +49-(0)751-3700 - 40 00
E-mail: info@vetter-pharma.com
www.vetter-pharma.com
About Vetter Pharma-Fertigung GmbH & Co. KG:
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. With about 1,900 employees worldwide, Vetter holds nearly 140 patents and has longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. In 2007, the company also received the go-ahead as a foreign manufacturer for the Japanese pharmaceutical market from Japan’s Ministry for Health, Labor and Welfare. Additionally, Vetter has received two awards for its new facility Ravensburg Vetter South (RVS): The Facility of the Year Award 2007 (Process Innovation category) and the European Outsourcing Award 2007 (Most Improved Process/Plant/Facility category).
Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions’ patented application systems enable clients to compete more effectively throughout the world. |
| |
| Almac win ‘Exporter of the Year’ in economic awards |
| |
Almac win ‘Exporter of the Year’ in economic awards
The Almac Group, headquartered in Craigavon Northern Ireland, with further sites across the UK and USA, is celebrating success after being named ‘Exporter of the Year’ by Northern Ireland’s economic development agency, Invest Northern Ireland.
The ‘Exporter of the Year’ award recognises outstanding export achievement and growth of a local business which have been exporting for over four years. It was one of five awards presented to local businesses as part of the Invest NI Innovation & Export Awards.
The achievement comes on the back of a successful 2008 for the group with export sales generating over 70% of the company turnover.
Almac are a major contributor to the Northern Ireland economy and are becoming increasingly important as it moves towards a high-value knowledge-based economy with strong potential for further development in the Pharma and Biotech sectors.
Almac’s Chief Executive Officer Alan Armstrong expressed pride in the recognition and said 2009 is going to be an exciting year for the company.
 Pictured L-R are Richard Ennis, Ulster Bank (awards sponsor), Martin Lamb, Almac and Rotha Johnston, Invest NI.
|
|
“As a Northern Ireland based company doing business with clients right across the globe, we have always understood the importance of developing existing export markets as well as exploring new export opportunities.
“This award from Invest NI is testament to the innovation of our company and the ingenuity of those working right across the Almac Group. For many years we have recognised the significance of building a balanced client portfolio right across the sector and this strategy is proving all the more important during the current downturn. We continue to recruit and have a positive outlook for the future. I would like to take this opportunity to offer my congratulations to all those working at Almac who make our success possible."
Contact:
Brendan Mulgrew / Carl Whyte
Stakeholder Communications
02890 339949 / 07767 393252
About Almac
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, product development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.
The company has almost 2,200 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $100m North American Headquarters started in July 08 and is expected to be completed 2010.
To find out more about Almac visit www.almacgroup.com |
| |
DHL secures £7m contract with Guy’s and St Thomas’ hospitals |
| |
DHL secures £7m contract with Guy’s and St Thomas’ hospitals
London, UK – 16th February 2009: DHL Exel Supply Chain, the world’s leading logistics services provider, has been awarded a five year hospital logistics contract with Guy’s and St Thomas’ Foundation Trust (GSTFT) - comprising two of London’s most well known teaching hospitals.
DHL will provide off-site cross docking of products from multiple suppliers, and - for medical surgical consumables - replenish the hospitals new Smart Store™ automated stock management systems. The solution will also control supplies held in operating theatres and wards, resulting in a leaner supply chain.
Glen McCracken, Business Manager, Hospital Managed Inventory Solutions, DHL Exel Supply Chain, said: “DHL is keen to deliver added value through dedicated operational support and unrivalled expertise in inventory management and lean hospital supply chains. Integral to the solution will be the use of DHL’s dedicated off-site facility at Park Royal which has ten years experience in supporting hospitals.”
The contract was awarded, following a competitive tender, on the basis of DHL’s experience and expertise in hospital logistics and its tailored, cost-effective solution for the Trust.
David Lawson, Director of Procurement, GSTFT, said: “The impressive track record of DHL’s hospital logistics hub at Park Royal was a key deciding factor during the selection process. The contract forms a key part of a wider strategy to fundamentally redesign the hospitals’ supply chain. The service will improve the reliability of the supply chain by helping the hospitals to proactively performance manage its suppliers.”
The contract will also drive the development of a fully integrated and multi-skilled internal logistics team - a central function in the success of the project.
“Our solution provides a dedicated team of people that will oversee replenishment, quality assurance and support functions. DHL understands the importance of people, both customer and staff, in influencing the success of the project which is why a strong emphasis on communication has been factored into the solution,” added Glen McCracken. |
|
 Media Inquiries:
DHL Press Office
T +44 (0) 207 413 3332
luke.baines@hillandknowlton.com
DHL
DHL is the global market leader of the international express and logistics industry, specializing in providing innovative and customized solutions from a single source.DHL offers expertise in express, air and ocean freight, overland transport, contract logistic solutions as well as international mail services, combined with worldwide coverage and an in-depth understanding of local markets. DHL's international network links more than 220 countries and territories worldwide. Some 300,000 employees are dedicated to providing fast and reliable services that exceed customers' expectations.
DHL is a Deutsche Post World Net brand. The group generated revenues of more than 63 bn euros in 2007.
www.dhl.co.uk
|
| |
| Dr. Paul Lohmann® adds Fermentation Grade Calcium Formate to its portfolio |
| |
Dr. Paul Lohmann® adds Fermentation Grade Calcium Formate to its portfolio
Dr. Paul Lohmann® has just added a new Calcium Formate grade to its product portfolio, especially
designed for the usage in fermentation purposes.
Usually Calcium Formate is a by-product to Pentaerythritol (Penta), and is mainly used in the feed
market and in the construction industry, where very basic qualities are applied.
For applications in the pharma sector but also for the fermentation of enzymes, a different quality is
required. This kind of product is not used from the above side stream, but is processed on-purpose by
Dr. Paul Lohmann® from the raw materials in order to ensure the required quality level.
Dr. Paul Lohmann® is the world’s leading provider of specialty mineral salts to the nutrition, dietary
supplement, pharmaceutical, cosmetic and technical industries. Over 120 years of manufacturing
experience – combined with innovation and flexibility – enables us to respond rapidly to the changing
market needs. We offer the broadest available portfolio of mineral salts: more than 350 in about
4000 qualities, designed to provide optimum performance across a wide range of applications.
Today we add one quality more: Fermentation Grade Calcium Formate.
Dr. Paul Lohmann GmbH KG |
|
Contact:
Dr. Paul Lohmann GmbH KG
Hauptstrasse 2
31860 Emmerthal
Germany
T: +49 5155 630
F: +49 5155 63345
sales@lohmann4minerals.com |
| |
| DHL expands healthcare offer with contract packing and kitting |
| |
DHL expands healthcare offer with contract packing and kitting
DHL Exel Supply Chain UK to launch extended solution nationally
London, UK – 22 January 2009: DHL Exel Supply Chain, the world’s leading logistics services provider, today announced the continued expansion of its contract cGMP (Good Manufacturing Practice Compliance) packing and kitting offering, which will now be available as a stand-alone service within its healthcare warehouses and distribution centers across the UK.
The solution has been offered for the past 12 years for customers seeking consolidated warehousing and packaging activities, providing improved efficiency and reduced waste. Due to increased capacity, DHL is now able to offer hand-based assembly, rework and co-packing as a stand-alone service to new and existing customers, covering pharmaceuticals, drug delivery systems, medical devices, surgical consumables and sample pack preparation. The solution includes secondary packaging, reworking, kitting and late customization to market or customer specific requirements.
DHL is licensed by the Medicines and Healthcare Products Regulatory Agency to conduct a range of cGMP packaging services. Licenses include commercial and clinical trial materials. DHL also has a number of Qualified Persons to release products following packaging activities.
Jonathan Blamey, Vice President Product Development Healthcare, DHL Exel Supply Chain EMEA, said: “At DHL, we pride ourselves on understanding our customers and offering tailored solutions according to their needs. This solution enhances our current healthcare offering, allowing more customers to utilize assembly and packaging, combined with storage and distribution, to deliver an integrated supply chain. This provides increased flexibility and responsiveness to market requirements.”
Caroline Fox, Technical Services Manager Healthcare, DHL Exel Supply Chain UK, said: “The solution offers our customers a cost-effective and consolidated supply chain that is backed by the expertise and knowledge of the world’s leading logistics services provider. For many customers, having a complete packaging and distribution service under one roof means reduced operating costs, with greater supply chain control and visibility.”
DHL Healthcare’s contract packing and kitting solution has already achieved success in various countries throughout Europe, including The Netherlands, Belgium, Italy and Turkey. |
|
Media Inquiries:
DHL Press Office
T +44 (0) 207 413 3332
luke.baines@hillandknowlton.com
DHL
DHL is the global market leader of the international express and logistics industry, specializing in providing innovative and customized solutions from a single source.
DHL offers expertise in express, air and ocean freight, overland transport, contract logistic solutions as well as international mail services, combined with worldwide coverage and an in-depth understanding of local markets. DHL's international network links more than 220 countries and territories worldwide. Some 300,000 employees are dedicated to providing fast and reliable services that exceed customers' expectations.
DHL is a Deutsche Post World Net brand. The group generated revenues of more than 63 bn euros in 2007.
www.dhl.co.uk |
| |
Key Almac division celebrates 20 years of growth |
| |
Almac Clinical Services now employs 1100 worldwide as it reaches its twentieth year
Almac Clinical Services, one of the key divisions at the Almac Group, has this month reached its twentieth year of operation. The Clinical Services division was founded in 1988 and has grown to become the largest and one of the most successful parts of the Almac family.
Originally operating with two employees in one location in Craigavon, the company now employs 1100 skilled individuals across three main operational centres – Craigavon (UK), Audubon (PA) and Durham (NC) in the US.
Almac Clinical Services has enjoyed exceptional year-on-year growth and continues to out-perform in the clinical supply marketplace in what has become an ever more challenging and competitive environment globally. The ongoing success has been built on a solid platform of providing service excellence to all clients irrespective of size, with Almac’s highly skilled and dedicated staff working within a quality ethos across all sites.
As Almac Clinical Services enters its third decade of operations, the company is now firmly established as a market leader in provision of world-class clinical services. Almac has recently announced further expansion with a new $110m North American Headquarters in the US, which will create hundreds of additional new jobs in Pennsylvania as well as further opportunities for existing staff.
Commenting on this milestone, Almac Clinical Services MD Dr Robert Dunlop said: “When we began trading as Clinical Trial Services, we competed in the market by offering all of our clients exceptional customer service. Although the service we provide has been complemented as technological and other advancements are made, that core commitment to customer services remains as strong as it was twenty years ago.
“Many of the staff who founded and contributed to the progress of our company are still with us today and have helped ensure Almac Clinical Services continues to occupy the market leading position it acquired many years ago.
“We congratulate all of those who have worked here over the past twenty years, both our dedicated staff and faithful clients alike. I am confident that over the next twenty years and beyond we will continue to develop the services that our market deserves and that our dedication to service will remain as strong as ever,” he added. |
|
Contact:
Carl Whyte
Stakeholder Communications
+44 (0)28 9033 9949
About Almac
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, product development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.
The company has almost 2,200 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company's new $100m North American Headquarters started in July 08 and is expected to be completed 2010.
To find out more about Almac visit www.almacgroup.com. |
| |
| BMG LABTECH is proud to announce the launch of the next generation HTS microplate reader - PHERAstar FS |
| |
BMG LABTECH Launches the New PHERAstar FS – The Next Generation HTS Microplate Reader.
BMG LABTECH, the world leader in microplate reader technology, launches the new top of the line HTS plate reader, the PHERAstar FS. It is based on the successful PHERAstar Plus and incorporates the following new features: Tandem Technology, which uses highly sensitive, Filter based detection in all modes and an industry first, ultra-fast UV/Vis Spectrometer; on-board reagent injectors for precise kinetic measurements; advanced bottom reading for cell-based assays; and a dedicated UV-laser for all TR-FRET based assays. To learn more about this exciting new reader visit us at booth 456 at Lab Automation 2009.
|
|
The PHERAstar FS performs all of the leading non-radioactive detection technologies, including fluorescence intensity, fluorescence polarization, time-resolved fluorescence / TR-FRET, laser-based AlphaScreenÒ, luminescence / BRET, and UV/Vis full spectrum absorbance. The PHERAstar FS achieves advanced performance in all reading modes, including HTRFÒ / TR-FRET, through an innovative lens-based optical system. This system is combined with a unique technology that ensures the optimal use of different mode-specific PMTs and excitation sources. In addition, BMG LABTECH readers are the only ones on the market that can capture TR-FRET decay curves in real-time for assay optimization. For HTS automation purposes, the PHERAstar FS is easily integrated into numerous robotic platforms or it can be equipped with BMG LABTECH's 50 plate Stacker II.
The PHERAstar FS is driven by BMG LABTECH’s well-known Reader Control software and data evaluation is performed by BMG’s exclusive Microplate Analysis and Reduction Software, MARS. The MARS Wizard creates an easy step-by-step calculation of a standard curve and the MARS Template Manager is an excellent tool for building complex data processing protocols. Thus, user-defined data analysis is one mouse click away. Enhanced robotic integration capabilities, digital signature, and the 21 CFR part 11 compliance of MARS complete this software package, making the PHERAstar FS the HTS reader of choice. Information about all BMG LABTECH´s microplate readers can be found on the company’s website: www.bmglabtech.com
AlphaScreen is a registered trademark of PerkinElmer, Inc.
HTRF is a registered trademark of Cisbio International. |
| |
| Hovione buys Pfizer’s Loughbeg API Facility |
| |
| Hovione buys Pfizer’s Loughbeg API Facility
Loures, Portugal, December 11th, 2008 - Hovione announced today that it has agreed with Pfizer to acquire their Loughbeg Active Pharmaceutical Ingredients (API) site in Ireland. This site manufactures intermediates for Lipitor active pharmaceutical ingredient.
The site has had a number of owners starting in 1984 with Angus Fine Chemicals, then Hickson & Welch, Warner Lambert, Pfizer and now Hovione. Over the last 10 years Pfizer has invested several hundred million dollars in plant and equipment there, making it a modern, well equipped site, meeting the highest standards in the industry. The deal is scheduled to be completed by early April 2009. Hovione Cork will employ 70-80 staff and will, over the next 24 months be transferring products from its Loures, Portugal site and validating processes for new compounds in expectation of drug approval. The terms of the transaction were not disclosed but Hovione will continue to provide manufacturing services for Pfizer.
"We made clinical trial materials for over 40 drug candidates last year. We have been investing heavily in R&D for over 6 years and now have a strong development pipe-line but have not invested in manufacturing assets since 2001, so it was time that we expanded our manufacturing capacity. This site offers everything that our Customers might want: large scale capacity, the highest standards, in a location where tax benefits are available to them and a well trained, innovative work-force" said Miguel Calado, CFO. The plant adds 427m3 of capacity to Hovione's 810m3 - of which 400m3 are in Portugal and the remainder in China. The plant is multi-purpose and is able to address a large number of specialized chemistries such as hydrogenation and low temperature chemistry. The Cork site also provides Hovione with a new, €70m capability to produce spray-dried formulations. Hovione is the world's leading provider of GMP spray-drying services covering every scale (lab, pilot and several intermediate production scales) and is able to provide R&D support and commercial manufacturing.
At a time when most fine chemical producers are investing in Asia, Hovione is turning to Ireland. Cork has the highest concentration of API production anywhere in the world, with a vast and deep talent pool, with an excellent cGMP record with the health authorities since the mid-nineties. These sites belong to Large Pharma, companies that are now embracing outsourcing as a key part of their long-term manufacturing strategy. Hovione believes that having the right kind of capacity in Cork will help it better serve its Innovator customers when it comes to making APIs for their new product introductions. "We have been manufacturing in China for over 25 years - we know very well what China can do for the Pharma industry, but we also know what it can't do - and it is for those reasons that we are now in Cork" said Guy Villax, Chief Executive, "The Cork site, the New Jersey Technology Transfer Centre, Loures in Portugal and Taizhou and Macau in China now provide Hovione with the right range of capabilities in the correct geographies - every site meets FDA requirements for APIs but every site is suited to a different and well defined mission" he added. |
|
Pharma manufacturing needs to become lean and cost-effective and this is always a challenge. The outsourcing business model gives manufacturers a head start, as contractors can provide their services to any Innovator company for any product and thus benefit from lower risk, better utilization of facilities and scale. In addition the contractor can select those compounds that have a good fit with its plant's technical capabilities, in turn the pharma company can avoid the expensive plant modifications often required to manufacture these compounds. It is this ability to produce for anyone that will contribute to making compounds fast and less expensively to the benefit of all stake-holders. However achieving this goal requires the ability to produce multiple small production campaigns -many simultaneously-, the skill to do rapid change-overs with validated cleaning, multi-purpose equipment design and lay-out that operate within a quality system specially designed for high levels of compliance yet of simple execution. This is what Hovione will be able to bring to the Cork site. "The combination of Hovione's 50 years of experience in API manufacture and contract manufacturing and the capabilities of the existing plant and compliance tradition of the Cork colleagues are a winning combination", said Noé Carreira, VP Manufacturing.
Hovione is an international group specializing in the development and compliant manufacture of active pharmaceutical ingredients, serving exclusively the pharmaceutical industry. With a 50-year track record, Hovione offers advanced technologies as well as APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe, the Far East and the US, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry and in particle engineering, Hovione offers all services related to the development, manufacture and pre-formulation of both new chemical entities (NCEs) and existing APIs for off-patent products.
For further information about Hovione, please visit the Hovione site at www.hovione.com or
contact Corporate Communications
(Isabel Pina,
+ 351 21 982 9362,
e-mail: hello@hovione.com). |
| |
| DPL Press Release Week 39 / 2008 |
| |
Dr. Paul Lohmann® announces the opening of the companies new FEA (research, development and application)
laboratory in June 2008 at their Emmerthal site in Germany. The FEA labs are dedicated to support customized
development programs for the companies customers in Pharma, Food and other application areas.
With the new laboratory facilities, Dr. Paul Lohmann® quintupled its lab capacity. The company is now able to
manage versatile research and development tasks according to customer inquiries. Furthermore, Dr. Paul
Lohmann® can offer its customers a cooperative development in the application technology labs on site in
Emmerthal. Particularly, Dr. Paul Lohmann® is now able to put a major focus on the development of nutritional
supplements and APIs.
“With this investment, Dr. Paul Lohmann aims at developing new solutions in cooperation with our customers to
increase profit and productivity of our partners by providing innovative and appropriate solutions for a large
variety of application fields”, said Dr. Uwe Günther, Company Executive and CTO of Dr. Paul Lohmann®. “Our
highly skilled FEA scientists are experts in their field and work in premises according to GMP and ISO standards
and dispose of cutting edge laboratory technology.”
|
|
Dr. Paul Lohmann® invites the industry to discuss individual product development scenarios at the trade shows
the company will be exhibiting in fall 2008:
| CPhI Worldwide - Frankfurt/Main, Germany |
September 30 - October 2, 2008
hall 5 / booth 50B01 |
| |
| Supply Side West - Las Vegas, NV, USA |
October 23 - 24, 2008
booth 16073 |
| |
| Health Ingredients - Europe, Paris, France |
November 4 - 6, 2008
hall 1 / booth E017 |
 |
| |
| Flexible design and delivery through Stralfors print innovation |
| |
|
|
Stralfors introduces FMsix, a new printing method which allows greater flexibility both in terms of delivery time and order size when printing cartons in many colours. Be just as creative in your designs as before, print identical colours time after time and forget the hassle of special repro or design files. See the results at ICSE 2008, exhibiting stand 41NE2.
Stralfors Pharmaceutical provides you with all your secondary packaging requirements and offer complementary services to create optimal solutions. Their new printing technology FMsix, to be launched at the ICSE in Frankfurt in September, combines the advantages of FM screening with a reduction of the number of colours used in order to print a high quality design. Now you can produce any design in a highly efficient and repetitive six-colour system, regardless of the number of spot colours originally used.
Mats Norell, Manager Stralfors Pharmaceutical in Sweden leads the team of production flow specialists that constantly reviews new technologies. ‘Our clients are looking for a strategic and innovative partner and FMsix forms a part of Stralfors’ recent technology investments which generate the quality and delivery improvements required by the industry. There is no room for inefficient production in the pharmaceutical sector, and pharmaceutical packaging is no exception’ he explains. |
|
For more information, please contact:
| Mats Norell |
Sales Manager Stralfors Pharmaceutical
Stralfors Pharmaceutical & Healthcare
Tel: +46 706 15 10 74
E-mail: mats.norell@stralfors.se |
| |
|
| Elin Johnsson |
Marketing Coordinator
Stralfors BA Labels
Tel: +46 706 85 06 95
E-mail: elin.johnsson@stralfors.se |
 Stralfors Business Concept
Stralfors, part of the Swedish Post Group Posten AB, is an IT-focused Business-to-Business company with print heritage, and providing total solutions within the field of information transfer. Stralfors develops, produces and delivers systems, services and products for the efficient communication of information crucial to
|
| |
| Stralfors presents the ultimate in pharmaceutical labelling |
| |
|
|
Stralfors presents the ultimate in pharmaceutical labelling
Stralfors launches the latest in labelling technology in the form of a multi-page label constructed in one piece. If you are looking for a remarkably secure and material efficient way to attach a lot of information to your product, you should visit Stralfors at ICSE 2008, exhibiting stand 41NE2. Stralfors Pharmaceutical is a leading supplier of secondary packaging solutions for the pharmaceutical industry.
The brand new label allows you to attach a multitude of information to your product without facing the risk of cross contamination in production. As the label has been constructed in one piece, it makes a material efficient and therefore cost-effective alternative to other multi-page labels. The construction also allows a better and more secure fit on the container, minimising the risk of lost and damaged information.
Hanne Wartenberg, Sales Manager at Stralfors Pharmaceutical in Denmark has followed the developments made by the one-piece product team consisting of technicians, production and quality control staff, amongst others. ‘Our clients realise that there is a lot of time and money to be saved using innovative processes throughout the production flow. The one-piece solution is a response to their requirements, aimed to give you that sometimes crucial difference in efficiency and security’ she explains.
Stralfors has shown its strong commitment to the pharmaceutical packaging sector by acquisitions of the internal printing department of Novo Nordisk and the printing businesses AB Cerbo Goteborg and Medigrafik A/S. Hanne Wartenberg explains that good partnering has taken the company to where it is today. ‘New solutions are continually formed between us and our clients. We often work with very rudimentary ideas for years in order to achieve the ultimate product for the industry’ she concludes. |
|
For more information, please contact:
Stralfors Business Concept
Stralfors, part of the Swedish Post Group Posten AB, is an IT-focused Business-to-Business company with print heritage, and providing total solutions within the field of information transfer. Stralfors develops, produces and delivers systems, services and products for the efficient communication of information crucial to operating a business. The Group has net sales of SEK 3.9 billion and 2300 employees at production sites in 8 countries.
|
| |
Thermo Fisher Scientific Announces its 2008 North American Informatics
Conference |
| |
PHILADELPHIA (August 11, 2008) – Thermo Fisher Scientific Inc., the world leader in serving science, has scheduled its annual North American laboratory Informatics user group meeting, Thermo Informatics World (TIW), from October 6-9, 2008 in Las Vegas, Nevada. The conference will not only profile the company’s strategic and product roadmaps, but also demonstrate its latest informatics offerings that address the growing data management and instrument integration challenges of today’s laboratories.
TIW North America 2008 will provide users with enhanced knowledge, tools and capabilities for integrating Thermo Scientific LIMS (laboratory information management systems) and CDS (chromatography data systems) across laboratory instruments and the enterprise, increasing collaboration and facilitating more informed decision making. This year’s theme is “where your solution is a sure thing.” Thermo Scientific LIMS and CDS are utilized in laboratories around the world and in diverse industries including chemicals, environmental, food and beverage, forensics, metals and mining, pharmaceuticals and bioanalytical, environmental and wastewater.
The management of data is a key factor influencing the overall productivity and performance of laboratories in all major industries. Demonstrating its proven expertise in the development of innovative laboratory software solutions at TIW 2008, Thermo Fisher Scientific will showcase its complete range of LIMS, CDS, pharmacokinetic-pharmacodynamic software systems, and spectroscopy software systems.
The North American TIW annual user conference provides industry professionals with a unique opportunity to share cross-sector perspectives and become informed on changing business requirements that drive the enhancements and future direction of Thermo Scientific informatics solutions. Designed to encourage customer involvement, TIW features product breakout sessions, including in-depth customer presentations, product updates and onsite training provided by the Thermo Fisher Scientific team of informatics experts.
TIW North America 2008 will take place at the JW Marriott Hotel in Las Vegas. Early bird registration is available until September, 5, 2008 and offers a savings of $300. Group discounts are also available. In addition, customers are invited to present on a range of topics from sharing tips for navigating the software to highlighting a successful implementation. Presenters will receive a waiver of the registration fee. |
|
For more information about TIW North America,
please call +1 866-463-6522
e-mail marketing.informatics@thermofisher.com
or register on-line at www.tiw08.com.
Thermo Scientific is part of | | |
